NXS Stock Overview
Engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Next Science Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.14 |
| 52 Week High | AU$0.50 |
| 52 Week Low | AU$0.12 |
| Beta | 1.51 |
| 11 Month Change | 14.00% |
| 3 Month Change | -36.67% |
| 1 Year Change | -49.11% |
| 33 Year Change | -88.32% |
| 5 Year Change | -93.49% |
| Change since IPO | -89.44% |
Recent News & Updates
Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper
Oct 22
Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce
Jul 26Recent updates
Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper
Oct 22Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce
Jul 26It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks
Jun 08Will Next Science (ASX:NXS) Spend Its Cash Wisely?
Apr 16Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce
Mar 06Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk
Dec 26Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%
Oct 26Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper
May 13The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts
Feb 03Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation
Jan 25Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future
Mar 07Here's Why We're Watching Next Science's (ASX:NXS) Cash Burn Situation
Feb 14
Did Next Science Limited (ASX:NXS) Insiders Buy Up More Shares?
Jan 18Do Institutions Own Next Science Limited (ASX:NXS) Shares?
Dec 20What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 23Shareholder Returns
| NXS | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -5.0% | 0.5% | 1.5% |
| 1Y | -49.1% | 14.2% | 17.2% |
Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| NXS volatility | |
|---|---|
| NXS Average Weekly Movement | 15.6% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NXS's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NXS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | I.V. Hall | www.nextscience.com |
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Next Science Limited Fundamentals Summary
| NXS fundamental statistics | |
|---|---|
| Market cap | AU$39.44m |
| Earnings (TTM) | -AU$20.76m |
| Revenue (TTM) | AU$35.84m |
1.2x
P/S Ratio-2.0x
P/E RatioIs NXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXS income statement (TTM) | |
|---|---|
| Revenue | US$23.31m |
| Cost of Revenue | US$4.93m |
| Gross Profit | US$18.37m |
| Other Expenses | US$31.87m |
| Earnings | -US$13.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 78.83% |
| Net Profit Margin | -57.93% |
| Debt/Equity Ratio | 0% |
How did NXS perform over the long term?
See historical performance and comparison